FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:968-969 September 23, 1993 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: For persistent mucocutaneous infections due to herpes simplex virus (HSV) in immunosuppressed patients, acyclovir is the drug of choice¹. Foscarnet is an alternative agent,^2,3 but it too may lead to resistance. A new approach to the therapy of HSV infections is based on the use of an acyclic nucleoside phosphonate, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), a potent and selective inhibitor of various DNA viruses, including HSV types 1 and 2 and thymidine kinase-deficient mutants of HSV^4,5.

We used HPMPC (1 percent, in Beeler base or Orabase), applied topically once a day on three consecutive days a week, to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Abadie, J. M., Koelsch, A. A. (2008). Performance of the Roche Second Generation Hemoglobin A1c Immunoassay in the Presence of Hb-S or Hb-C Traits. Annals of Clinical & Laboratory Science 38: 31-36 [Abstract] [Full Text]  
• De Clercq, E. (2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev. 16: 569-596 [Abstract] [Full Text]  
• Liekens, S., Neyts, J., De Clercq, E., Verbeken, E., Ribatti, D., Presta, M. (2001). Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir. Cancer Res. 61: 5057-5064 [Abstract] [Full Text]  
• Nowatzke, W. L., Parvin, C. A., Scott, M. G., Hock, K., Cole, T. G. (2001). Correction of Positive Bias of the Roche Tina-quant II Hemoglobin A1c (HbA1c) Assay at Low HbA1c Percentages. Clin. Chem. 47: 976-978 [Full Text]  
• Andrei, G., Snoeck, R., De Clercq, E., Esnouf, R., Fiten, P., Opdenakker, G. (2000). Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81: 639-648 [Abstract] [Full Text]  
• Lateef, F., Don, P. C., Kaufmann, M., White, S. M., Weinberg, J. M. (1998). Treatment of Acyclovir-Resistant, Foscarnet-Unresponsive HSV Infection With Topical Cidofovir in a Child With AIDS. Arch Dermatol 134: 1169-1170 [Full Text]  
• Chen, D., Crimmins, D. L., Hsu, F. F., Lindberg, F. P., Scott, M. G. (1998). Hemoglobin Raleigh as the cause of a falsely increased hemoglobin A1C in an automated ion-exchange HPLC method. Clin. Chem. 44: 1296-1301 [Abstract] [Full Text]  
• Neyts, J., Andrei, G., De Clercq, E. (1998). The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo. Antimicrob. Agents Chemother. 42: 216-222 [Abstract] [Full Text]  
• Rossi, S., Whitfeld, M., Berger, T. G. (1995). The Treatment of Acyclovir-Resistant Herpes Zoster With Trifluorothymidine and Interferon Alfa. Arch Dermatol 131: 24-26 [Abstract]